Literature DB >> 7252421

Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity.

H Perlmann, P Perlmann, R D Schreiber, H J Müller-Eberhard.   

Abstract

The occurrence and distribution of distinct receptors for three C3 fragments on purified human blood lymphocytes were studied by rosette formation. Indicator cells were bovine, chicken, or sheep erythrocytes (E) bearing up to 100,000 molecules of human C3b (EC3b) without antibody. EC3b was converted to C3bi-bearing-E (EC3bi) with purified C3b inactivator (factor I) and beta1H (factor H), and to C3d-bearing E (EC3d) by treatment of EC3bi with trypsin. Using bovine E (Eb) as indicators, approximately 11% of the lymphocytes bound EbC3b, 6% bound EbC3bi and 2% bound EbC3d. Fractionation of the lymphocytes by adsorption to monolayers of C3-fragment-bearing Eb or by rosetting indicated that most of the cells with receptors for C3b were distinct from those having receptors for C3bi and/or C3d. Cells from two lymphoblastoid cell lines (Raji and Daudi) formed strong rosettes with EC3b, which were weak. 51Cr-labeled E was used as a target in antibody, C3-fragment-bearing E was not lysed by the lymphocytes. However, at suboptimal concentrations of IgG enhancing capacity of the fragments occurred in the order of C3bi greater than C3d greater than C3b. In addition, C3-fragment-bearing cells inhibited the lysis of antibody-coated cells not concluded that target cell bound C3 fragments enhance ADCC by improving contact between target cells and those effector cells which have C3 receptors. Cell-bound C3 effector cells. It is proposed that certain lymphocytes are capable of interacting with C3bi in addition to C3b and C3d and that C3bi and C3d have a greater regulatory effect on their cytolytic function than C3b.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7252421      PMCID: PMC2186201          DOI: 10.1084/jem.153.6.1592

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Complement (C3) receptor-bearing lymphocyte-mediated cytotoxicity and lymphotoxin responses.

Authors:  P O'Neill; B F Mackler; P Wyde
Journal:  Cell Immunol       Date:  1975-11       Impact factor: 4.868

2.  Antibody-mediated cell cytotoxicity in a defined system: regulation by antigen, antibody, and complement.

Authors:  H J Lustig; C Bianco
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

3.  Lymphocyte mediated cytotoxicity in vitro. Induction and inhibition by humoral antibody and nature of effector cells.

Authors:  P Perlmann; H Perlmann; H Wigzell
Journal:  Transplant Rev       Date:  1972

4.  Evaluation of C3 receptors on lymphoid cells with different complement sources.

Authors:  M P Dierich; M A Pellegrino; S Ferrone; R A Reisfeld
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

5.  Antibody-dependent lymphoid cell-mediated cytotoxicity: role of complement.

Authors:  J A Van Boxel; W E Paul; I Green; M M Frank
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

6.  Immune adherence by the fourth component of complement.

Authors:  N R Cooper
Journal:  Science       Date:  1969-07-25       Impact factor: 47.728

7.  Cytolytic lymphocytic cells with complement receptor in human blood. Induction of cytolysis by IgG antibody but not by target cell-bound C3.

Authors:  P Perlmann; H Perlmann; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-02-01       Impact factor: 14.307

8.  Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.

Authors:  R D Schreiber; R G Medicus; O Gïtze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

9.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism.

Authors:  A N Theofilopoulos; F J Dixon; V A Bokisch
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

View more
  28 in total

1.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Dissociation of IgG antibody-mediated clumps of Trypanosoma brucei gambiense by complement.

Authors:  T Takayanagi; H Kawaguchi; Y Yabu; M Itoh; K Yano
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

3.  A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer.

Authors:  Michelle Elvington; Yuxiang Huang; B Paul Morgan; Fei Qiao; Nico van Rooijen; Carl Atkinson; Stephen Tomlinson
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

4.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

5.  Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation.

Authors:  T Morimura; C Neuchrist; K Kitz; H Budka; O Scheiner; D Kraft; H Lassmann
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

6.  Interactions between soluble IgG, complement and cells in lymphocyte and monocyte ADCC.

Authors:  R N Poston; R S Morgan
Journal:  Immunology       Date:  1983-11       Impact factor: 7.397

7.  Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.

Authors:  O F Ramos; G Sármay; E Klein; E Yefenof; J Gergely
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

Review 8.  CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions.

Authors:  G D Ross; V Vĕtvicka
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.

Authors:  J J Weis; T F Tedder; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

10.  In vivo effect of sera from animals with chronic relapsing experimental allergic encephalomyelitis on central and peripheral myelin.

Authors:  H Lassmann; K Kitz; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1981       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.